Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

As part of its OncView™ video series, CancerNetwork^® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved mobocertinib.

In the video series, Gregory Riely, MD, PhD, and Tarek Mekhail, MD, discussed the following:

• Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design
• Efficacy Data From the EXCLAIM Cohort in mNSCLC
• EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC
• EXCLAIM Cohort in mNSCLC: Treatment Selection and Management
• mNSCLC: Biomarker Testing and Patient Adherence to TKIs
• Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC

To watch more videos in the CancerNetwork^® Between the Lines™ series, visit cancernetwork.com/oncview.